サルコペニア治療薬市場:パイプライン分析・治験・特許・指定・協力・動向

P&S Market Researchが発行した調査報告書(PSM804045)
◆英語タイトル:Sarcopenia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
◆商品コード:PSM804045
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2018年2月
◆ページ数:81
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD1,850 ⇒換算¥209,050見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はP&S Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

The study analyzed that the sarcopenia therapeutics pipeline comprises of 13 drug candidates in different stages of development. Further, the analysis also states that the pipeline has around 15% of the drug candidates that are being developed as gene therapy.
Insights on Pipeline Segments

Novartis AG, and Regeneron Pharmaceuticals Inc., have one drug candidate each in the Phase II stage of development for the treatment of the disease. In December 2017, Biophytis SAS announced that the Federal Agency for Medicines and Health Products (FAMHP) approved to conduct the SARA-INT Phase II interventional study of sarcopenia in Belgium.

Sarcopenia therapeutics Pipeline Marked by Positive Clinical Trials Results

The drugs being developed by the various pharmaceutical companies for the treatment of sarcopenia have demonstrated positive clinical trial results which in-turn aids in their further development. For instance, In June 2017, Novartis AG announced the positive results of a 24-week randomized, double-blind, placebo-controlled, parallel-arm, proof-of-concept study of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. In February 2016, ATA 842 demonstrated increased muscle mass and muscle strength in the treatment of young and old mice in four weeks.

Rise in Patent Approvals for Sarcopenia Therapeutics Expected to Provide Collaborative Opportunities to the Pharmaceutical Companies

It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of sarcopenia. For instance, in June 2016, Novartis AG received patent for the invention related to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of age-related sarcopenia (WO2015IB59369 20151204). Patent approval helps in increasing opportunities for invention improvement and uniqueness for the pharmaceutical companies.

Some of the key players developing drugs for the treatment of sarcopenia include Novartis AG, Biophytis SAS and Vibe Pharmaceuticals LLC.

【レポートの目次】

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.2 Sign & Symptoms

4.3 Epidemiology

4.4 Pathophysiology

4.5 Diagnosis

4.6 Prevention and Treatment

4.7 Key Drivers

4.7.1 Technological Advancements

4.7.2 Increased Funding from Government Bodies and Private Sector

4.8 Key Barriers

4.8.1 Safety Concerns

4.9 Sarcopenia Therapeutics Pipeline Analysis

4.9.1 Pipeline Analysis by Phase

4.9.2 Pipeline Analysis by Molecule Type

4.9.3 Pipeline Analysis by Route of Administration

4.9.4 Pipeline Analysis by Company

Chapter 5. Sarcopenia Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase II

5.1.1 Bimagrumab

5.1.1.1 Pre-Clinical trial results

5.1.1.2 Clinical trials

5.1.1.3 Clinical trials results

5.1.1.4 Strategic development

5.1.2 XXXXX

5.1.2.1 Clinical trials

5.2 Phase I

5.2.1 Sarcone

5.2.1.1 Pre-Clinical results

5.2.1.2 Clinical trials

5.2.1.3 Clinical trial results

5.2.1.4 Strategic development

5.2.1.5 Technology

5.2.2 XXXXX

5.2.2.1 Strategic development

5.2.2.2 Technology

5.3 Pre-Clinical

5.3.1 Enzyme/Protein Replacement Therapy for Sarcopenia – Immusoft Corporation

5.3.1.1 Technology

5.3.1.2 Strategic development

5.3.2 XXXXX

5.3.2.1 Pre-Clinical studies

5.3.2.2 Strategic development

5.3.3 XXXXX

5.3.3.1 Technology

5.3.3.2 Strategic development

5.3.4 XXXXX

5.3.4.1 Pre-Clinical results

5.3.4.2 Strategic development

5.4 Discovery

5.4.1 VB-102

5.4.1.1 Technology

5.4.2 XXXXX

5.4.2.1 Strategic developments

5.4.2.2 Technology

5.4.3 XXXXX

5.4.4 XXXXX

5.5 Unknown

5.5.1 XXXXX

5.5.1.1 Technology

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Sarcopenia Therapeutics Pipeline

7.2 SWOT Analysis of Sarcopenia Therapeutics Pipeline

Chapter 8. Company Profiles

8.1 Biophytis SAS

8.1.1 Business Overview

8.1.2 Products and Service Offerings

8.2 Vibe Pharmaceuticals LLC

8.2.1 Business Overview

8.2.2 Products and Service Offerings

8.3 Neurotune AG

8.3.1 Business Overview

8.3.2 Products and Service Offerings

8.4 XXXXX

8.4.1 Business Overview

8.4.2 Products and Service Offerings

8.5 XXXXX

8.5.1 Business Overview

8.5.2 Products and Service Offerings

8.6 XXXXX

8.6.1 Business Overview

8.6.2 Product and Service Offerings

8.7 Novartis AG

8.7.1 Business Overview

8.7.2 Product and Service Offerings

8.8 XXXXX

8.8.1 Business Overview

8.8.2 Product and Service Offerings

8.9 XXXXX

8.9.1 Business Overview

8.9.2 Products and Service Offerings

8.10 XXXXX

8.10.1 Business Overview

8.10.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

List of Tables

TABLE 1 PIPELINE ANALYSIS OF SARCOPENIA THERAPEUTICS, BY COMPANY (2018)

TABLE 2 DESCRIPTION OF BIMAGRUMAB

TABLE 3 CLINICAL TRIALS OF BIMAGRUMAB

TABLE 4 DESCRIPTION OF XXXXX

TABLE 5 DESCRIPTION OF SARCONE

TABLE 6 DESCRIPTION OF XXXXX

TABLE 7 DESCRIPTION OF ENZYME/PROTEIN REPLACEMENT THERAPY FOR SARCOPENIA – IMMUSOFT CORPORATION

TABLE 8 DESCRIPTION OF XXXXX

TABLE 9 DESCRIPTION OF XXXXX

TABLE 10 DESCRIPTION OF XXXXX

TABLE 11 DESCRIPTION OF VB-102

TABLE 12 DESCRIPTION OF XXXXX

TABLE 13 DESCRIPTION OF XXXXX

TABLE 14 DESCRIPTION OF XXXXX

TABLE 15 DESCRIPTION OF XXXXX

TABLE 16 BIOPHYTIS SAS – AT A GLANCE

TABLE 17 VIBE PHARMACEUTICALS LLC – AT A GLANCE

TABLE 18 XXXXX– AT A GLANCE

TABLE 19 XXXXX– AT A GLANCE

TABLE 20 XXXXX– AT A GLANCE

TABLE 21 XXXXX– AT A GLANCE

TABLE 22 NOVARTIS AG – AT A GLANCE

TABLE 23 XXXXX– AT A GLANCE

TABLE 24 XXXXX– AT A GLANCE

TABLE 25 XXXXX – AT A GLANCE

List of Figures

FIG 1: RESEARCH METHODOLOGY

FIG 2: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4: SARCOPENIA DRUG CANDIDATES IN DEVELOPMENT (2018)

FIG 5: SARCOPENIA PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6: SARCOPENIA PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 8: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 9: KEY PLAYERS BENCHMARKING

FIG 10: SWOT ANALYSIS



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ サルコペニア治療薬市場:パイプライン分析・治験・特許・指定・協力・動向(Sarcopenia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆